	US 12,458,650 B2
	Urination disorder-improving agent
Hideo Kobayashi, Kanagawa (JP); Atsushi Shinbo, Kanagawa (JP); Youichi Nakano, Kanagawa (JP); Yuta Ito, Kanagawa (JP); and Junichi Watanabe, Kanagawa (JP)
Assigned to ASKA PHARMACEUTICAL CO., LTD., Tokyo (JP)
Appl. No. 17/764,659
Filed by ASKA Pharmaceutical Co., Ltd., Tokyo (JP)
PCT Filed Jan. 29, 2020, PCT No. PCT/JP2020/003105 § 371(c)(1), (2) Date Mar. 29, 2022, PCT Pub. No. WO2021/065027, PCT Pub. Date Apr. 8, 2021.
Claims priority of application No. 2019-182369 (JP), filed on Oct. 2, 2019.
Prior Publication US 2022/0331340 A1, Oct. 20, 2022
Int. Cl. A61K 31/573 (2006.01); A61K 31/585 (2006.01); A61P 13/02 (2006.01); A61P 13/10 (2006.01)

CPC A61K 31/573 (2013.01) [A61K 31/585 (2013.01); A61P 13/02 (2018.01); A61P 13/10 (2018.01)]

7 Claims

1. A method of improving a urination disorder, the method comprising administering a therapeutically effective amount of a urination disorder-improving agent comprising 17α-acetoxy-6-chloro-15ß-hydroxy-2-oxa-4,6-pregnadiene-3,20-dione as an active ingredient to a subject.